论文部分内容阅读
目的探讨多西他赛加表阿霉素加环磷酰胺(TEC方案)行新辅助化疗在局部晚期乳腺癌治疗中的疗效观察。方法 38例未经治疗的IIb—IIIc期的局部晚期乳腺癌予TEC方案行新辅助化疗。入组患者化疗前均接受肿瘤原发灶空芯针穿刺活检并取得病理组织学确诊。结果 TEC方案新辅助化疗在局部晚期乳腺癌的治疗中总有效率84.2%,其中临床完全缓解15.8%(6/38),临床部分缓解63.2%(24/38),病理完全缓解5.3%(2/38)。主要的毒副反应为白细胞减少、脱发和恶心、呕吐,无败血症和死亡病例。结论 TEC方案新辅助化疗在局部晚期乳腺癌的治疗中疗效显著,耐受性好。
Objective To investigate the efficacy of docetaxel plus epirubicin plus cyclophosphamide (TEC regimen) in neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. Methods Thirty-eight patients with untreated IIb-IIIc locally advanced breast cancer were treated with neoadjuvant chemotherapy. Before chemotherapy, all the patients in the group received core needle puncture biopsy of the tumor and confirmed histopathologically. Results The total effective rate of neoadjuvant chemotherapy for TEC was 84.2% in the treatment of locally advanced breast cancer, of which 15.8% (6/38) were clinically completely relieved, 63.2% (24/38) partially relieved, and 5.3% completely relieved / 38). The main side effects are leucopenia, hair loss and nausea, vomiting, sepsis and deaths. Conclusion The TEC regimen neoadjuvant chemotherapy is effective in the treatment of locally advanced breast cancer and is well tolerated.